Literature DB >> 16150772

Open label extension studies: research or marketing?

G J Taylor1, P Wainwright.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Year:  2005        PMID： 16150772      PMCID： PMC1200598          DOI： 10.1136/bmj.331.7516.572

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Consent to open label extension studies: some ethical issues.

Authors:  P Wainwright
Journal:  J Med Ethics       Date:  2002-12       Impact factor: 2.903

2.  The ethical problems of the open label extension study.

Authors:  K C Micetich
Journal:  Camb Q Healthc Ethics       Date:  1996       Impact factor: 1.284

3.  Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care?

Authors:  Joseph C Blader
Journal:  Contemp Clin Trials       Date:  2005-03-03       Impact factor: 2.226
  3 in total
  11 in total

Review 1.  Open-label extension studies: do they provide meaningful information on the safety of new drugs?

Authors:  Richard O Day; Kenneth M Williams
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis.

Authors:  Fernanda S Tonin; Laiza M Steimbach; Leticia P Leonart; Vinicius L Ferreira; Helena H Borba; Thais Piazza; Ariane G Araújo; Fernando Fernandez-Llimos; Roberto Pontarolo; Astrid Wiens
Journal:  Eur J Clin Pharmacol       Date:  2018-07-18       Impact factor: 2.953

Review 3.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

Review 4.  Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.

Authors:  Noor Alsalimy; Ahmed Awaisu
Journal:  Int J Clin Pharm       Date:  2014-10-07

5.  Expanded Access Programme: looking for a common definition.

Authors:  Antonella Iudicello; Lucia Alberghini; Giulia Benini; Paola Mosconi
Journal:  Trials       Date:  2016-01-12       Impact factor: 2.279

Review 6.  Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?

Authors:  Vitor Ennes-Vidal; Rubem Figueiredo Sadock Menna-Barreto; Marta Helena Branquinha; André Luis Souza Dos Santos; Claudia Masini D'Avila-Levy
Journal:  Parasitology       Date:  2016-11-21       Impact factor: 3.234

Review 7.  Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Nian N N Maarof; Abdulsamad Alsalahi; Emilia Abdulmalek; Sharida Fakurazi; Bimo Ario Tejo; Mohd Basyaruddin Abdul Rahman
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

Review 8.  Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration.

Authors:  Kanecia O Zimmerman; P Brian Smith; Ann W McMahon; Jean Temeck; Debbie Avant; Dianne Murphy; Susan McCune
Journal:  JAMA Pediatr       Date:  2019-01-01       Impact factor: 26.796

Review 9.  Drug repurposing and human parasitic protozoan diseases.

Authors:  Katherine T Andrews; Gillian Fisher; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-24       Impact factor: 4.077

10.  Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.

Authors:  Kathryn Coyle; Doug Coyle; Julie Blouin; Karen Lee; Mohammed F Jabr; Khai Tran; Lisa Mielniczuk; John Swiston; Mike Innes
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.